EMA Validation of ENHERTU Breast Cancer Treatme...

By HEOR Staff Writer

February 20, 2026

EMA Validates ENHERTU Breast Cancer Treatment Variation The European Medicines Agency (EMA) has validated a Type II Variation marketing authorization application for ENHERTU br...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Genotype ECG Prediction
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
South Africa Health Reform: Navigating Innovations and Challenges for 2026